Ocular Changes in TgF344-AD Rat Model of Alzheimer's Disease

Yunchun Tsai, Cedars Sinai Regenerative Medicine Institute
Bin Lu, Cedars Sinai Regenerative Medicine Institute
Alexander V. Ljubimov, Cedars Sinai Regenerative Medicine Institute
Sergey Girman, Cedars Sinai Regenerative Medicine Institute
Fred N. Ross-Cisneros, University of Southern California
Alfredo A. Sadun, University of Southern California
Clive N. Svendsen, Cedars Sinai Regenerative Medicine Institute
Robert Cohen, Emory University
Shaomei Wang, Cedars Sinai Regenerative Medicine Institute

Journal Title: Investigative Ophthalmology & Visual Science
Volume: Volume 55, Number 1
Publisher: AVRO Journals | 2014-01-01, Pages 523-534
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1167/iovs.13-12888
Permanent URL: https://pid.emory.edu/ark:/25593/vkd2j

Final published version: http://dx.doi.org/10.1167/iovs.13-12888

Copyright information:
© 2014 The Association for Research in Vision and Ophthalmology, Inc.

Accessed July 8, 2024 5:12 AM EDT
Alzheimer’s disease (AD) is the leading cause of dementia, which is characterized by loss of memory and a progressive decline in cognitive function. To date, over 26 million people are estimated to suffer from AD, and the number is expected to quadruple by 2050.1 The characteristic lesions in AD are amyloid-β (Aβ) plaque deposition, formation of neurofibrillary tangles (NFTs), neuronal loss, and inflammation, all of which lead to degeneration of neurons and synapses in the brain.2 In addition to cognitive and behavioral deficits, vision disturbances have been reported in early stages of AD even before the diagnosis is clearly established.3,4 Visual examinations in patients with AD have revealed anomalies in visual acuity,1 contrast sensitivity,5 color vision,6 and motion perception.7 Armstrong et al.8 suggested that senile plaques and NFTs are dominant in the cuneal gyrus, which is consistent with the inferior field defects in AD.9 However, whether visual problems in AD are related to cortical disease or retinal abnormalities remains controversial. Indeed, increasing evidence indicates that retinal changes such as degeneration and loss of retinal ganglion cells (RGC),10–12 reduction of the retinal nerve fiber layer (RNFL) thickness,13–15 and reduced retinal blood flow16 may partially account for visual dysfunctions17 in AD patients, as in those affected with some other neurodegenerative diseases, including demyelinating optic neuritis, multiple sclerosis, and Parkinson disease.18

Recently, the pathogenesis of AD has been focused on cerebral vasculature and the manifestations in the choroid plexus (CP), in connection with the deficient clearance of Aβ across the blood-brain barrier19,20 and the blood-cerebrospinal fluid (CSF) barrier.21,22 Atrophy of epithelial cells leads to CP abnormalities and alteration of synthesis, secretion and transportation of proteins. As the eye and the brain share many features in terms of embryological origin, anatomical, and physiological characteristics,18 investigating the changes of ocular vasculature in AD might shed light on the pathological mechanisms.

In the past decade, transgenic (Tg) mouse models overexpressing mutant forms of amyloid precursor protein (APP) and/or presenilin 1 (PS1) have been generated to mimic various aspects of AD pathology, including Aβ deposition, cognitive

Ocular Changes in TgF344-AD Rat Model of Alzheimer’s Disease

Yuchun Tsai,1 Bin Lu,1 Alexander V. Ljubimov,1,2 Sergey Girman,1 Fred N. Ross-Cisneros,3 Alfredo A. Sadun,3 Clive N. Svendsen,1,2 Robert M. Cohen,4 and Shaomei Wang1

1Cedars-Sinai Regenerative Medicine Institute, Los Angeles, California
2David Geffen School of Medicine at UCLA, Los Angeles, California
3Doheny Eye Institute and Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California
4Emory University, Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia

Correspondence: Shaomei Wang, Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, AHSP-8107, Los Angeles, CA 90048; shaomei.wang@cshs.org.

Submitted: July 22, 2013
Accepted: December 17, 2013

several studies have shown the activated glial cells in different strains of Tg animals. Retinal vasculature, loss of retinal ganglion cells, and AlexaFluor 568-conjugated donkey anti-rabbit IgG 1:300 Dianova FITC-conjugated goat anti-mouse IgG 1:300 Dianova Mouse anti-RT97 1:1000 Millipore Mouse anti-GFAP 1:500 Sigma Rabbit anti-C3 complement 1:300 Santa Cruz Mouse anti-CD68 1:300 Abcam with 4% paraformaldehyde in PBS, followed by postfixation of gliosis, and neuronal loss that parallel those in humans. Nevertheless, none of these mouse models faithfully recapitulate the pathology of AD patients. Here, we examined the changes in the eye using a novel Tg AD rat model, TgF344-AD, which has a healthy long lifespan but suffers cognitive decline at later ages, age-dependent cerebral amyloidosis, taupathy, which has a healthy long lifespan but suffers cognitive decline at later ages, age-dependent cerebral amyloidosis, taupathy, gliosis, and neuronal loss that parallel those in humans. Deposition of Aβ plaques in both brains and eyes, reduction of choroidal thickness, hypertrophy of RPE cells and inflammatory response in choroid are described here in the Tg rats. Importantly, the reduction of choroidal thickness was observed in retinas of postmortem eyes from AD patients, although using a limited sample size.

Materials and Methods

Transgenic Rats

We used 19-month-old Tg rats (of both males and females) and age-matched WT controls for visual function tests. At least eight eyes were examined in each group. For histological analysis, 14- and 19-month-old rats were used and at least 12 eyes were analyzed in each group. The heterozygous TgF344-AD rats on a Fischer-344 background used in this study coexpress human APP 695 with mutations (K595N, M596L), as the antigen was purified from EHS tumor matrix that does not contain 3(IV)25(IV) chains.93 This is the major isoform in choriocapillaris and Bruch’s membrane.94 Deficits, inflammation, and synaptic dysfunction.23 Likewise, several studies have shown the Aβ deposits in the retina24 and retinal vasculature,25 loss of retinal ganglion cells,25 and activated glial cells in different strains of Tg animals. Nevertheless, none of these mouse models faithfully recapitulate the pathology of AD patients. Here, we examined the changes in the eye using a novel Tg AD rat model, TgF344-AD, which has a healthy long lifespan but suffers cognitive decline at later ages, age-dependent cerebral amyloidosis, taupathy, gliosis, and neuronal loss that parallel those in humans.25 Deposition of Aβ plaques in both brains and eyes, reduction of choroidal thickness, hypertrophy of RPE cells and inflammatory response in choroid are described here in the Tg rats. Importantly, the reduction of choroidal thickness was observed in retinas of postmortem eyes from AD patients, although using a limited sample size.

Visual Functional Analysis

Visual acuity was tested by optokinetic response (OKR) on both Tg and WT rats according to our published protocol.26 Luminance threshold recordings from the superior colliculus (SC) were obtained using our previous protocol.29

Light Microscopical Immunohistochemistry

Rats were euthanized with CO2 and transcardially perfused with 4% paraformaldehyde in PBS, followed by postfixation of the eyes and brains in the same fixative for 1 hour and overnight, respectively. Tissues were cryoprotected in PBS with 30% sucrose overnight at 4°C. Samples were then embedded in OCT and cut into 10-µm sections on a cryostat (Leica CM1850; Leica Microsystems, Wetzlar, Germany). The sections were collected according to our previous protocol.30 One slide from each set was stained with cresyl violet (CV) to assess integrity of retinal lamination; the rest of the slides stored at −40°C were used for immunohistochemistry. The same protocol was applied for brain sections, but section thickness was 30 µm. For Aβ plaque staining, sections were blocked with 5% horse serum (HS) with 0.25% Triton X-100 for 1 hour at room temperature and incubated overnight at 4°C with the primary 6E10 anti-Aβ antibody. For controls, retinal sections were processed as above, but without primary antibody or with diaminobenzidine (DAB) only. Retinal sections were then incubated with the secondary antibody coupled with biotin for 1 hour at room temperature followed by avidin–biotin enhancer complex coupled with HRP (ABC Elite; Vector Laboratories, Burlingame, CA) for 1 hour at room temperature. After 30 minutes of washing with PBS, DAB (Vector Laboratories) was added and the reaction was stopped in distilled water after 5 minutes of washing. Slides were lightly counterstained with CV, dehydrated, mounted using CV mount medium, and examined by regular light microscopy.

Immunofluorescence and Confocal Microscopic Imaging

Retinal sections were permeabilized and blocked with 10% HS with 0.25% Triton X-100 for 1 hour at room temperature and then incubated with primary antibodies or PBS as control overnight at 4°C followed by secondary antibodies for 1 hour at room temperature, with DAPI nuclear counterstaining. Primary and secondary antibodies used in this study are listed in Table 1. Retinal sections were mounted with fluorescent mounting medium (DAKO, Carpinteria, CA) for imaging. Images were taken with a confocal microscope (Eclipse C1si; Nikon Instruments, Inc., Melville, NY) and a fluorescence microscope (Olympus BX61; Olympus America, Inc., Center Valley, PA).

Retrograde Labeling With Neuronal Tracer and Retinal Whole Mount Preparation

To quantify the number of RGC, a neuronal tracer (Fluoro-Gold; Fluorochrome, LLC, Denver, CO) was applied to the SC as described.31 Briefly, the animals were anesthetized, placed into a stereotactic apparatus, and the skull was cut. A small piece of gelatin sponge soaked in 3% neuronal tracer (Fluorochrome, LLC) was laid over the center of SC, and a retinal whole mount was prepared 5 days after surgery as follows. Animals were perfused with PBS, followed by 4% paraformaldehyde. The orientation of the eye was marked. The eyes were flattened by four radial cuts and the entire retina was removed under the dissecting microscope. The retina was postfixed for 30 minutes in the same fixative and infiltrated in 30% sucrose at 4°C. Before blocking, the whole mount retina was frozen at −80°C for 15 minutes to assist antibody penetration, followed by immunofluorescent staining as described above.

Quantification

To measure the thickness of choroid in the retinal sections, at least seven retinal sections from each animal cut in the same horizontal angle across optic nerve were stained with type IV collagen antibody and the fluorescence signal was measured by Java-based image processing software version 1.46 (ImageJ; National Institutes of Health [NIH], Bethesda, MD). The
thickness of the retinal choroid was measured according to the published protocol and rat sections were collected as we previously described. Briefly, four cryostat sections (50 μm apart) were collected per slide providing five 1 in 4 series. One series was stained with CV for assessing integrity of retinal lamination, the rest was stained for antibodies. Approximately 80 slides were generated per eye with one series of 16 slides. The thickness of the choroid was defined as the distance between the outer border of the Bruch's membrane and the inner border of the sclera. Measurements were performed by Java-based image processing software version 1.6 (NIH). The values for each eye were averaged and the statistical analysis was performed. The total number of Iba-1 positive cells (microglia) in the choroid were assessed for every 10th retinal section in the WT and Tg animals. At least five eyes were examined in WT and Tg rats, respectively. Counting of RGCs was adapted from the previously published procedure for the rat retina. Briefly, images of six standard rectangular areas from the optic disc in the central regions of each retinal quadrant were captured. All neuronal tracer–labeled (Fluorochrome, LLC) RGCs were counted using a cell-counter plugin based on Java-based imaging software (NIH). The total number of RGCs was summed up and statistical analysis was performed between WT and Tg groups.

**Human Autopsy Specimens**

Human postmortem control eyes were received from the Lions Vision Gift eye bank in Portland, Oregon, and the AD eyes were acquired through the Alzheimer's Disease Research Center (ADRC) Neuropathology Core at the University of Southern California (USC) or National Disease Research Interchange (NDRI, Philadelphia, PA). The ADRC at USC is funded by the National Institute of Aging. The acquisition of donor tissue through the ADRC at USC has been approved by an Institutional Review Board (IRB) at USC. The Lions Vision Gift eye bank enucleates from the anterior aspect of the orbit and the ADRC from the posterior side. Prior to enucleation, both the Lions Vision Gift eye bank and ADRC initially dissect away the conjunctiva, extraocular muscles, and surrounding connective tissues and minor nerves. Then both groups enucleate the eyes by cutting away the optic nerves and gently extracting the tissues from the orbit anteriorly or posteriorly. The
posterior extraction of the eye performed by the ADRC occurs after the removal of the brain. Furthermore, both tissue banks immersion fix the eyes in neutral buffered formalin, and all tissues are dissected, processed, embedded into paraffin, and sectioned by the same laboratory. NDRI supplied nonfixed eyes in corneal storage medium (Optisol-GS, Chiron IntraOptics, Irvine, CA). Six patients with AD (aged 63, 64, 75, 80, 80, and 95 years) and six age-matched control subjects (aged 64, 76, 80, 85, 93, and 95 years) at autopsy (postmortem interval 3–13 hours) were analyzed. The diagnosis of AD was confirmed clinicopathologically in accordance with modified Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) or National Institute on Aging (NIA)-Reagan criteria and Braak-Braak Alzheimer classification.34,35 Age-matched eyes that were from patients not having a diagnosis of AD served as control specimens in the study. Neither the patients with AD nor the patients from whom the control tissues were obtained had any history of diabetes mellitus, metastatic cancers, ocular diseases, or sepsis. Eyes were immersion-fixed in 10% neutral buffered formalin immediately following enucleation. Posterior extraction of the eye performed by the ADRC occurs after the removal of the brain. Furthermore, both tissue banks immersion fix the eyes in neutral buffered formalin, and all tissues are dissected, processed, embedded into paraffin, and sectioned by the same laboratory. NDRI supplied nonfixed eyes in corneal storage medium (Optisol-GS, Chiron IntraOptics, Irvine, CA). Six patients with AD (aged 63, 64, 75, 80, 80, and 95 years) and six age-matched control subjects (aged 64, 76, 80, 85, 93, and 95 years) at autopsy (postmortem interval 3–13 hours) were analyzed. The diagnosis of AD was confirmed clinicopathologically in accordance with modified Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) or National Institute on Aging (NIA)-Reagan criteria and Braak-Braak Alzheimer classification.34,35 Age-matched eyes that were from patients not having a diagnosis of AD served as control specimens in the study. Neither the patients with AD nor the patients from whom the control tissues were obtained had any history of diabetes mellitus, metastatic cancers, ocular diseases, or sepsis. Eyes were immersion-fixed in 10% neutral buffered formalin immediately following enucleation. Eyes were dissected at the horizontal meridian through the optic nerve and nasal and temporal regions of the retina. Tissues were then processed for paraffin embedding, cut at 5 μm on a retracting microtome, and prepared for immunohistochemistry. After dewaxing in xylene, rehydrating in decreasing grades of ethanol, and antigen retrieval, the same antibodies used for rat tissues targeting epitopes for type IV collagen, RPE65, and Aβ (6E10) were also used for human tissues. The thickness of choroid was measured using the same method as described above for the rat tissues. Four fresh eyes from AD donors (age: 79 and 79 years) and four fresh eyes from normal controls (age: 78 and 83 years) were prepared for whole-mount staining with Thioflavin-T according to protocol described by Picket and Herrera,36 and Aβ (6E10) antibody using the protocol above.

**Statistical Analysis**

Statistical analysis (with $P < 0.05$ considered significant) was performed with unpaired, two-tailed Student’s t-test. Error bars indicate SEM. Asterisks indicate significance, *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$.

**RESULTS**

**Accumulation of Aβ Deposits in the Eyes of TgF344-AD Tg Rat**

We first wanted to confirm that there was a buildup of Aβ in the brain and retina of the AD rats as shown previously for the AD mouse.24–26 Immunofluorescent staining with anti-human Aβ plaque-specific antibody 6E10 showed no positive staining in the WT rat brain (Figs. 1A, 1B); in contrast, robust deposition of Aβ plaques with variable sizes in both hippocampus (Fig. 1C) and cortex (Fig. 1D) was detected in the TgF344-AD rat brain. Using the same antibody in the retina, no immunoreactivity was found in the WT retinas (Fig. 1E), whereas the senile plaque-like staining was found in the inner plexiform layer (IPL), outer plexiform layer (OPL), and choroid (Figs. 1F–H) of 19-month-old Tg rats. Only few amyloid plaques were observed in 14-month-old Tg rats. There was no positive signal detected (Supplementary Fig. S1) in negative controls (PBS to replace the primary antibody and/or the secondary antibody).

The same antibody was applied to human postmortem retinas from both AD patients and age-matched controls, with brain sections from Tg rat as positive control. Virtually no Aβ plaques were found in non-AD human retinal sections as revealed by anti-human Aβ plaque-specific antibody 6E10 staining of retinal whole mounts. Plaque-like structures (Supplementary Figs. S2A, S2B versus control C-without primary antibody) were found in two retinas from two AD patients, with denser morphology than those seen in Tg rat brain. Further analysis revealed that there were two and 27 plaque-like structures per retinal whole-mount in these two AD cases, which could reflect the disease severity. Thioflavin-T staining failed to detect positive staining in the other two retinas from these two AD patients. However, this result may have been influenced by standard acid treatment during Thioflavin-T staining.

**Visual Function Is Impaired in the Rat Model of AD**

We next established whether visual acuity of Tg rats was altered relative to age-matched WT rats by testing OKR at age 19 months. Spatial frequency thresholds declined to approximatively 0.15 cyc/deg in Tg rats, compared with 0.22 cyc/deg in WT rats (Fig. 2A), and this difference was significant ($P < 0.005$). Contrast sensitivity was increased in 19-month-old Tg rats (>$50\%$) compared with WT rats (15%–18%; preliminary observation on limited rats). This is an interesting observation. Further study is needed to confirm this difference. In order to examine whether retinal sensitivities to light stimuli are altered in AD eyes, luminance thresholds were also recorded in both WT and Tg rats (age 19 months). The thresholds were viable across the SC in both groups (Figs. 2B, 2C) from 0.1 to 0.6 and

---

**FIGURE 2.** Visual dysfunction in TgF344-AD rats. (A) Spatial visual acuity was recorded using Optometry head tracking apparatus. In 19-month-old Tg rats, spatial visual acuity was significantly declined compared with age-matched WT rats (mean ± SEM, $n = 8$, ***$P \leq 0.01$). To measure retinal sensitivity to light across the visual field, a single and multunit activities of luminance threshold responses were recorded at 16 points within the SC from 19-month-old WT (B) and Tg (C) rats. Although retinal sensitivities in Tg rats were reduced compared with WT rats, uneven luminance thresholds across the superior colliculus were observed in both Tg and control rats.
**FIGURE 3.** The retinal sections were double stained with antibodies against type IV collagen (red) and RPE65 (green) in WT (A) and Tg (B) rats. The boxes correspond to the high power images, which show obvious reduction in choroidal thickness in Tg (B1, B2) than in WT rats (A1, A2). Nuclei were counterstained with DAPI (blue). Scale bars: 50 µm. (C) Measurements of the choroidal thickness from 14- and 19-month-old Tg and age-matched WT rats revealed that there was significant difference between Tg and WT groups at both age groups. Mean ± SEM, n = 5. *P ≤ 0.05, **P ≤ 0.01 compared with WT rats of both ages.
-0.1 to 0.5 log units in Tg rats and WT, respectively. Overall, there was no difference on the retinal sensitivities to light stimuli between Tg and WT rats.

**Morphological Changes in the RPE Cells and Choroid of the AD Rat**

Previous studies have shown abnormal inner retinal pathologies in various AD Tg mouse models.\(^{24-26}\) No prior studies have reported changes in the outer retina. Ocular histopathology assessments of the TgF344-AD rats and age-matched WT rats in this study were performed at the age of 14 (\(n = 6\)) and 19 (\(n = 5\)) months. To assess the thickness of the choroid, the immunoreactivity of choroidal vessels was evaluated following basement membrane-specific antibody staining for type IV collagen. Overall, the thickness of the choroid was uneven across the retina; it was thinner in the peripheral part than in the central retina. Interestingly, at 19 months, the thickness of the choroid in Tg rats was significantly reduced to 36.13 ± 1.71 μm (Figs. 3A, 3C), compared with 48.6 ± 3.74 μm (\(P < 0.01\)) in age-matched WT rats (Figs. 3B, 3C). This change has already been detected at 14 months, with choroidal thickness of 41.7 ± 2.96 μm in Tg rats and 63.57 ± 14.01 μm in WT rats (\(P < 0.05\); Fig. 3C).

The monolayer of RPE wrapping around the outer retina and forming part of the blood-retinal barrier is important for fine visual acuity, visual cycle, and homeostasis.\(^{37}\) To assess the morphological changes of RPE, retinal sections were stained with cresyl violet (Figs. 4A, 4B) and the RPE-specific marker RPE65 (Figs. 4C, 4D). In 19-month-old WT rats, RPE cells were flat and had few double nucleated cells (Figs. 4A, 4C). By comparison, in Tg rats RPE cells showed hypertrophy, and cells with double nuclei were more frequently found (Figs. 4B, 4D). The changes in the RPE cells were not observed in the limited human retinas.

**Changes in Eyes From Patients With Alzheimer's Disease**

To determine whether a similar pattern of choroid thinning was present in human tissues, 12 human retinas (seven male, and five female) aged 63–95 years were analyzed. The mean choroidal thickness decreased from 122.36 ± 24.87 μm to 84.75 ± 4.35 μm with aging (Table 2) in control donors. The mean thickness in normal samples was 98.79 ± 7.00 μm and was reduced to 73.17 ± 8.92 μm in AD samples (\(P < 0.05\); Table 2). Although the sample size is small, the results parallel those from rats, with thinning of choroid in AD retinas.
compared with age-matched controls. With the same protocol as above, retinal sections from both age-matched controls (Supplementary Fig. S3A) and AD (Supplementary Fig. S3B) were stained with antibodies against RPE65 and type IV collagen. The multiple nuclei of RPE cells often observed in Tg rat were not seen in AD retinas (Supplementary Fig. S3).

**Table 2.** Choroidal Thickness in Human Postmortem Retinas

<table>
<thead>
<tr>
<th>Age, y/Sex</th>
<th>Mean Choroidal Thickness, μm</th>
<th>Age, y/Sex</th>
<th>Mean Choroidal Thickness, μm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ctrl 64 F</td>
<td>122.36 ± 24.87</td>
<td>AD 63 M</td>
<td>91.57 ± 0.19</td>
</tr>
<tr>
<td>Ctrl 76 M</td>
<td>94.34 ± 1.60</td>
<td>AD 64 F*</td>
<td>41.56 ± 0.05</td>
</tr>
<tr>
<td>Ctrl 80 M</td>
<td>84.75 ± 4.35</td>
<td>AD 75 F</td>
<td>85.50 ± 3.96</td>
</tr>
<tr>
<td>Ctrl 85 M</td>
<td>79.66 ± 6.39</td>
<td>AD 80 M</td>
<td>55.30 ± 2.59</td>
</tr>
<tr>
<td>Ctrl 93 F</td>
<td>108.44 ± 3.75</td>
<td>AD 80 M</td>
<td>68.52 ± 5.34</td>
</tr>
<tr>
<td>Ctrl 95 F</td>
<td>107.19 ± 5.36</td>
<td>AD 95 F</td>
<td>96.75 ± 1.10</td>
</tr>
</tbody>
</table>

* Ctrl, control; F female; M, male.

* The patient had glaucoma.

Other Significant Changes in the Eyes of TgF344-AD Rats

One of the main features accompanying deposition of Aβ plaques in AD is an inflammatory response characterized by infiltration of microglia and activation of complement. Therefore, we examined the expression of Iba-1 and CD68, general and activated microglia-specific markers, respectively, and performed quantitative analysis to evaluate the infiltration of microglia. Figures 5A through 5D shows representative pictures of Iba-1 and CD68 immunoreactivity in WT and Tg rats. Similar to the infiltration of microglia in the inner retinas of AD mice, significantly increased Iba-1 immunoreactivity was detected in the choroid of Tg rats (Figs. 5B, 5E). In addition, activated microglia or neutrophils were also significantly increased in Tg rats based on CD68-positive signals (Figs. 5D, 5F). In the complement system, C3 is the key activator of the common and alternative pathways. Immunofluorescent labeling showed that C3 deposition along the Bruch's membrane was increased in Tg rats compared with age-matched WT rats (Figs. 5G, 5H).

**Structural Observations in the Retina and Choroid of the AD Rat**

To visualize the general retinal lamination, retinal sections were stained with cresyl violet. The uneven photoreceptor cell loss across the retina was observed in both aged WT and Tg rats (Figs. 6A, 6B). The photoreceptor loss was more prominent in the peripheral part of the retina with one to three layers of cells, whereas around the optic nerve head, the photoreceptors were about six to eight cells thick. The overall retinal lamination was still maintained in both WT and Tg rats. We did not detect the uneven loss of photoreceptors in AD retinas, although the inner nuclear layer (INL) seems to be much thinner (one to three layers) than in healthy controls (three to five layers, Supplementary Figs. S3A versus S3B). The reason for the thinning INL and any relation with pathology of AD needs further study.

Retinal blood flow studies have described a significant narrowing of the veins and reduced venous blood flow rate in AD patients. However, we did not see obvious difference in the RGC numbers between WT and Tg eyes (Figs. 6D, 6F).

Upregulation of glial fibrillary acidic protein (GFAP) expression in the retinal Müller glial cells has been well documented in a variety of retinal insults including injury, diabetic retinopathy, aging, and degeneration. In the WT rats at 19 months, there were active Müller glial cells as revealed by GFAP staining (Fig. 5E); while in TgF344-AD rats, the expression of GFAP in radial Müller glia was more evident than in WT animals (Figs. 5I, 5J).

**DISCUSSION**

In the present study, we showed for the first time a marked thinning of retinal choroid and hypertrophic RPE in TgF344-AD rat, a novel rat model that manifests the spectrum of age-dependent AD pathologies. The similar thinning of the choroid was also observed in a limited series of human postmortem specimens. Detection of Aβ plaques in the retinas and brains of Tg rats was confirmed by 6E10 antibody, which exhibited a similar staining pattern to a mouse model of AD. Aβ deposition in the retina may explain the increase in inflammation, complement activation, and a decline of visual function in the Tg rats, although no apparent neuronal cell loss was observed in RGC based on neuronal tracer (Fluorochrome, LLC) labeling. One study has found Aβ plaques deposition in human retina, and we have also seen plaque-like staining in two AD retinal whole mounts as revealed by anti-human Aβ plaque-specific antibody 6E10. Regardless of the mechanism of how Aβ becomes detrimental to the retina, our results highlight the pathological changes in the outer retina associated with AD.

**Changes in Choroid and RPE Layer**

The choroid is one of the most highly vascularized tissues of the body, provides oxygen and nourishment to the outer retina, modulates retinal temperature, secretes growth factors, and adjusts the retinal position. The choroid is involved in the pathogenesis of various ocular diseases such as pathological myopia, glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and age-related choroidal atrophy. In the case of type 2 diabetes, the decreased choroidal blood flow may occur before the clinical manifestations of diabetic retinopathy. In addition, the loss of choriocapillaris could increase vascular resistance, resulting in decreased blood flow. The observations of pathological variations in choroidal thickness suggested that the choroidal thickness could be an important parameter in the evaluation of ocular and other diseases. Interestingly, numerous structural and functional cerebral microvascular abnormalities have been identified since microvascular perturbations have been highlighted in AD over 25 years ago. The topographic associations of capillaries and neuritic plaques are highly correlated, and abnormalities of blood vessels are evident before the formation of parenchymal amyloid plaques in a Tg mouse model of AD. Indeed, robust microvascular Aβ deposition in the retina of Tg mice was well documented in the line Tg2576. From these studies, we hypothesize that the changes in the retinal choroid and Aβ deposition in the retina could be relevant to the pathologies observed in the brain. On the other hand, not only ocular diseases but also aging causes the decrease of choroidal thickness, which has been documented in several studies. Although the choroidal changes are small relative to other severe symptoms, they may play an important role in the visual regulation and eventually affect visual function.
FIGURE 5. Infiltration of inflammatory cells and activation of C3 complement in 19-month-old Tg rats. Retinal sections were stained for Iba-1 (red; [A], [B]) and CD68 (green; [C], [D]). An increase of Iba-1 and CD68 signal was observed in Tg rats ([B], [D]). Quantification of the Iba-1 ([E]) and CD68 ([F]) positive cells in the choroid of 14- and 19-month-old Tg and age-matched WT rats revealed significant differences between Tg and WT rats in both age groups (mean ± SEM, n = 4. *P ≤ 0.05, ***P ≤ 0.001). Retinal sections stained with antibody against C3 (red) and counterstained with DAPI (blue) showed an activated C3 complement signal along the RPE layer in Tg rat ([H]) compared with WT control ([G]). GFAP staining showed more obvious upregulation of the protein expression in radial Müller glia in Tg rat ([J]) compared with WT control ([I]). Scale bars: 50 μm.
RPE cell dysfunction is relevant to various retinal degenerative diseases, which illustrates the importance of the RPE for photoreceptor viability. RPE hypertrophy is a cardinal feature of the stress response triggered by various perturbations, such as iron accumulation and oxidative damage. Interestingly, injection of oligomeric Aβ peptide into the subretinal space of B6 mice induces RPE hypertrophy and pigmentation loss but not apoptosis, which supports the idea of oxidative stress involvement in the alterations of RPE function. Although aging also leads to abnormal RPE function, we found more frequent RPE hypertrophy in 14 and 19 months TgF344-AD rats compared with age-matched WT control rats (Fig. 4), which underline the effect of Aβ on RPE dysfunction. Furthermore, RPE hypertrophy has also been described in advanced AMD in humans and may occur earlier in the progress of the disease. Thus, the morphological and functional changes in RPE cells are likely to be a characteristic of ocular and neurodegenerative disease.

Visual Acuity and Inner Retinal Changes

Visual acuity varies with different strains in animal models. Indeed, the Fischer-344 rats with albinism showed poorer visual acuity than pigmented rats. In the TgF344-AD rats, visual acuity was lower than in age-matched WT rats (Fig. 2). However, the fundamental mechanisms underlying the Aβ pathology association with visual acuity need further studies. The thinning choroid may contribute the poor visual performance as well. Morphologically, we saw uneven loss of photoreceptors across the retina, which correlated with the data from luminance threshold recording. Although the luminance thresholds were elevated in both Tg and WT rats...
compared with pigmented WT rats, there are compensatory mechanisms within retinal circuitry and the superior colliculus since the retinal responses to light stimulation are still rather sensitive. We did not observe the uneven loss of photoreceptors in human AD retinas, which indicates the limitation of this rat model. Although AD transgenic animal models show similarities across various studies, variations of the onset of the amyloid plaque formation and retinal changes in different lines are presumably explained by differences in animal strains, promoters, and specific mutations used. Also, animal models may not faithfully recapitulate the pathology of human patients. The RGC loss has been described in AD patients and in some animal models of AD. In TgF344-AD rats, no obvious changes in the RGC numbers compared with age-matched WT rats were observed. This result is in agreement with data from APPswe/PS1ΔE9 Tg mouse study, which showed the absence of significant neuronal loss. Again, the current rat and mouse models for AD do not appear to recapitulate the full pathology of human patients. Recent reports suggested that RGC dendritic atrophy may precede cell loss, calling for further studies to examine the morphology of RGC.

**Immunological Responses**

A role for inflammation in the pathogenesis of AD is suggested by the presence of activated microglia and proinflammatory cytokines, chemokines, and complement proteins in the brain of AD patients, which are not evident in the normal brain. Microglia have been found to be preferentially associated with certain amyloid plaque types. Once microglial cells are activated, the secretion of inflammatory cytokines, such as TNF-α and IL-1β, contributes to Aβ deposition and the early pathogenic changes in AD. Nevertheless, activated microglia can also be beneficial by phagocytosis of Aβ and secretion of anti-inflammatory factors. The activation of complement system involved in neuronal death at the early stages of AD has also been reported in human and Tg animal studies. Notably, we observed the recruitment of microglia and the activation of complement protein C in the choroid suggesting an inflammatory response in the ocular vascular system. Although the main causes and progression of the inflammatory response in the AD eye are still unclear, it is possible that chronic ocular inflammation early in life may set the stage later for the development of AD.

**Implications**

In the clinical application, the optical coherence tomography (OCT) provides a noninvasive, noncontact, transpupillary imaging modality to monitor retinal changes. Since the introduction of enhanced depth imaging based on OCT (EDI-OCT) technology by Spaide, changes in choroidal vasculature and volume have been reported in choriodetinal disorders accurately and reproducibly. In humans, some studies have indicated that choroidal thickness is dynamic and influenced by the time of the day. Retinal location, and age. Accordingly, for the future diagnostic purpose, the above factors should be considered.

In summary, we have observed pathological changes in the choroid and RPE cells in TgF344-AD rat model, and the same choroidal thinning in a limited number of human AD retinas. Along with Aβ deposition, the inflammatory response manifested by microglial recruitment and complement activation was seen in the choroid. Further study is needed to investigate the mechanisms of these ocular changes and their relation with changes in the brain. The long-term goal will be to aid early diagnosis of AD by studying the eye, the approachable part of the brain.

**Acknowledgments**

The authors thank Terrence Town, PhD, and Tara M. Weitz, PhD (University of Southern California, Keck School of Medicine, Los Angeles, CA) for sharing tissue from 14-month-old AD rats. We thank Claudia Tan and Mary Bessell for proofreading this manuscript, and Carol Church and Jeanette Espinosa for their administrative support at the Alzheimer’s Disease Research Center at the University of Southern California.

Supported by Grants NIH R01 EY020488-02, W81XWH-DOD, the Lincy Foundation, FFB, the Fund from the Regenerative Medicine Institute at Cedars-Sinai Medical Center, the National Institute of Aging Grant P50-AG05142, and NIH R01 EY05040 (FNR-C and AAS).

Disclosure: Y. Tsai, None; B. Lu, None; A.V. Ljubimov, None; S. Girman, None; F.N. Ross-Cisneros, None; A.A. Sadun, None; C.N. Swendsen, None; R.M. Cohen, None; S. Wang, None

**References**


